
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 14, 2022, titled "Glenmark inks agreement with Astrazeneca to commercialize its product PulmicortRespules in Columbia".
Filed with NSE ·

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 14, 2022, titled "Glenmark inks agreement with Astrazeneca to commercialize its product PulmicortRespules in Columbia".
6ix hasn’t read this filing yet.
Glenmark Pharmaceuticals Limited on 6ix
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals